Small intestinal bacterial overgrowth in patients suffering from scleroderma: Clinical effectiveness of its eradication

Andrea Parodi, Marta Sessarego, Alfredo Greco, Marco Bazzica, Gilberto Filaci, Maurizio Setti, Edoardo Savarino, Francesco Indiveri, Vincenzo Savarino, Massimo Ghio

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

OBJECTIVES: After the skin, the gastrointestinal tract is the second most common target of systemic sclerosis (SSc). AIM: Our aims were to investigate orocecal transit time (OCTT) and the presence of small intestinal bacterial overgrowth (SIBO) in SSc as a cause of intestinal symptoms. METHODS: Fifty-five SSc patients and 60 healthy controls, sex and age matched, entered the study. Enrolled subjects completed a questionnaire for intestinal symptoms and a global symptomatic score (GSS) was calculated. OCTT and the presence of SIBO were assessed by a lactulose breath test (LBT). Patients with SIBO were treated with rifaximin 1,200 mg/day for 10 days. Finally, a second questionnaire and LBT were performed 1 month after the end of therapy. RESULTS: The prevalence of SIBO was higher in SSc patients compared with controls (30/54 vs 4/60, respectively, P <0.001). OCTT was significantly slower in SSc patients compared with controls (150 min, 25-75th percentile 142.5-165 vs 105 min, 25-75th percentile 90-135, respectively, P <0.001). In patients with SIBO, the median GSS score was 8 (25-75th percentile 3.25-10.75). Eradication of SIBO was achieved in 73.3% of patients, with a significant reduction of symptoms in 72.7% of them (GSS score 2, 25-75th percentile 1-3, P <0.05). CONCLUSIONS: These data suggest that SIBO occurs more frequently in SSc patients than in controls. Intestinal symptoms in these patients may be related to this syndrome and its eradication seems useful to improve clinical features. OCTT is significantly delayed in SSc patients, suggesting an impairment of intestinal motility, a further risk factor for the development of SIBO.

Original languageEnglish
Pages (from-to)1257-1262
Number of pages6
JournalAmerican Journal of Gastroenterology
Volume103
Issue number5
DOIs
Publication statusPublished - May 2008

Fingerprint

Systemic Scleroderma
Lactulose
Breath Tests
rifaximin
Gastrointestinal Motility
Gastrointestinal Tract
Skin

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Small intestinal bacterial overgrowth in patients suffering from scleroderma : Clinical effectiveness of its eradication. / Parodi, Andrea; Sessarego, Marta; Greco, Alfredo; Bazzica, Marco; Filaci, Gilberto; Setti, Maurizio; Savarino, Edoardo; Indiveri, Francesco; Savarino, Vincenzo; Ghio, Massimo.

In: American Journal of Gastroenterology, Vol. 103, No. 5, 05.2008, p. 1257-1262.

Research output: Contribution to journalArticle

Parodi, A, Sessarego, M, Greco, A, Bazzica, M, Filaci, G, Setti, M, Savarino, E, Indiveri, F, Savarino, V & Ghio, M 2008, 'Small intestinal bacterial overgrowth in patients suffering from scleroderma: Clinical effectiveness of its eradication', American Journal of Gastroenterology, vol. 103, no. 5, pp. 1257-1262. https://doi.org/10.1111/j.1572-0241.2007.01758.x
Parodi, Andrea ; Sessarego, Marta ; Greco, Alfredo ; Bazzica, Marco ; Filaci, Gilberto ; Setti, Maurizio ; Savarino, Edoardo ; Indiveri, Francesco ; Savarino, Vincenzo ; Ghio, Massimo. / Small intestinal bacterial overgrowth in patients suffering from scleroderma : Clinical effectiveness of its eradication. In: American Journal of Gastroenterology. 2008 ; Vol. 103, No. 5. pp. 1257-1262.
@article{eb56ea62c427478e91f1c965b45ef189,
title = "Small intestinal bacterial overgrowth in patients suffering from scleroderma: Clinical effectiveness of its eradication",
abstract = "OBJECTIVES: After the skin, the gastrointestinal tract is the second most common target of systemic sclerosis (SSc). AIM: Our aims were to investigate orocecal transit time (OCTT) and the presence of small intestinal bacterial overgrowth (SIBO) in SSc as a cause of intestinal symptoms. METHODS: Fifty-five SSc patients and 60 healthy controls, sex and age matched, entered the study. Enrolled subjects completed a questionnaire for intestinal symptoms and a global symptomatic score (GSS) was calculated. OCTT and the presence of SIBO were assessed by a lactulose breath test (LBT). Patients with SIBO were treated with rifaximin 1,200 mg/day for 10 days. Finally, a second questionnaire and LBT were performed 1 month after the end of therapy. RESULTS: The prevalence of SIBO was higher in SSc patients compared with controls (30/54 vs 4/60, respectively, P <0.001). OCTT was significantly slower in SSc patients compared with controls (150 min, 25-75th percentile 142.5-165 vs 105 min, 25-75th percentile 90-135, respectively, P <0.001). In patients with SIBO, the median GSS score was 8 (25-75th percentile 3.25-10.75). Eradication of SIBO was achieved in 73.3{\%} of patients, with a significant reduction of symptoms in 72.7{\%} of them (GSS score 2, 25-75th percentile 1-3, P <0.05). CONCLUSIONS: These data suggest that SIBO occurs more frequently in SSc patients than in controls. Intestinal symptoms in these patients may be related to this syndrome and its eradication seems useful to improve clinical features. OCTT is significantly delayed in SSc patients, suggesting an impairment of intestinal motility, a further risk factor for the development of SIBO.",
author = "Andrea Parodi and Marta Sessarego and Alfredo Greco and Marco Bazzica and Gilberto Filaci and Maurizio Setti and Edoardo Savarino and Francesco Indiveri and Vincenzo Savarino and Massimo Ghio",
year = "2008",
month = "5",
doi = "10.1111/j.1572-0241.2007.01758.x",
language = "English",
volume = "103",
pages = "1257--1262",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Small intestinal bacterial overgrowth in patients suffering from scleroderma

T2 - Clinical effectiveness of its eradication

AU - Parodi, Andrea

AU - Sessarego, Marta

AU - Greco, Alfredo

AU - Bazzica, Marco

AU - Filaci, Gilberto

AU - Setti, Maurizio

AU - Savarino, Edoardo

AU - Indiveri, Francesco

AU - Savarino, Vincenzo

AU - Ghio, Massimo

PY - 2008/5

Y1 - 2008/5

N2 - OBJECTIVES: After the skin, the gastrointestinal tract is the second most common target of systemic sclerosis (SSc). AIM: Our aims were to investigate orocecal transit time (OCTT) and the presence of small intestinal bacterial overgrowth (SIBO) in SSc as a cause of intestinal symptoms. METHODS: Fifty-five SSc patients and 60 healthy controls, sex and age matched, entered the study. Enrolled subjects completed a questionnaire for intestinal symptoms and a global symptomatic score (GSS) was calculated. OCTT and the presence of SIBO were assessed by a lactulose breath test (LBT). Patients with SIBO were treated with rifaximin 1,200 mg/day for 10 days. Finally, a second questionnaire and LBT were performed 1 month after the end of therapy. RESULTS: The prevalence of SIBO was higher in SSc patients compared with controls (30/54 vs 4/60, respectively, P <0.001). OCTT was significantly slower in SSc patients compared with controls (150 min, 25-75th percentile 142.5-165 vs 105 min, 25-75th percentile 90-135, respectively, P <0.001). In patients with SIBO, the median GSS score was 8 (25-75th percentile 3.25-10.75). Eradication of SIBO was achieved in 73.3% of patients, with a significant reduction of symptoms in 72.7% of them (GSS score 2, 25-75th percentile 1-3, P <0.05). CONCLUSIONS: These data suggest that SIBO occurs more frequently in SSc patients than in controls. Intestinal symptoms in these patients may be related to this syndrome and its eradication seems useful to improve clinical features. OCTT is significantly delayed in SSc patients, suggesting an impairment of intestinal motility, a further risk factor for the development of SIBO.

AB - OBJECTIVES: After the skin, the gastrointestinal tract is the second most common target of systemic sclerosis (SSc). AIM: Our aims were to investigate orocecal transit time (OCTT) and the presence of small intestinal bacterial overgrowth (SIBO) in SSc as a cause of intestinal symptoms. METHODS: Fifty-five SSc patients and 60 healthy controls, sex and age matched, entered the study. Enrolled subjects completed a questionnaire for intestinal symptoms and a global symptomatic score (GSS) was calculated. OCTT and the presence of SIBO were assessed by a lactulose breath test (LBT). Patients with SIBO were treated with rifaximin 1,200 mg/day for 10 days. Finally, a second questionnaire and LBT were performed 1 month after the end of therapy. RESULTS: The prevalence of SIBO was higher in SSc patients compared with controls (30/54 vs 4/60, respectively, P <0.001). OCTT was significantly slower in SSc patients compared with controls (150 min, 25-75th percentile 142.5-165 vs 105 min, 25-75th percentile 90-135, respectively, P <0.001). In patients with SIBO, the median GSS score was 8 (25-75th percentile 3.25-10.75). Eradication of SIBO was achieved in 73.3% of patients, with a significant reduction of symptoms in 72.7% of them (GSS score 2, 25-75th percentile 1-3, P <0.05). CONCLUSIONS: These data suggest that SIBO occurs more frequently in SSc patients than in controls. Intestinal symptoms in these patients may be related to this syndrome and its eradication seems useful to improve clinical features. OCTT is significantly delayed in SSc patients, suggesting an impairment of intestinal motility, a further risk factor for the development of SIBO.

UR - http://www.scopus.com/inward/record.url?scp=43549089508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43549089508&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2007.01758.x

DO - 10.1111/j.1572-0241.2007.01758.x

M3 - Article

C2 - 18422815

AN - SCOPUS:43549089508

VL - 103

SP - 1257

EP - 1262

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 5

ER -